Skip to content
Open access

Affinity-Based Proteome Profiling to Identify Targets of Tuberculosis Antibiotics

Oct 2026 · ACS Infectious Diseases · 0 citations · 25 references

TL;DR

This work constructed photo-cross-linker probes containing a minimalist diazirine and an alkynyl handle of four TB drugs─pretomanid, linezolid, moxifloxacin, and one newly identified inhibitor, BB2-50F, with diverse chemical structures and mechanisms of action and validated that these probes retain on-target activity against M. tuberculosis in growth and viability assays.

Abstract

Drug-resistant Mycobacterium tuberculosis is an increasing global health crisis that requires the urgent development of new antibiotics. Understanding the mechanism of action of new inhibitors is an essential but challenging component of drug discovery. Affinity-based proteome profiling (AfBP) is a powerful approach for target identification involving the cross-linking and selective pull-down of covalently bound target proteins. Here, we sought to investigate its utility as a technique to identify protein targets of tuberculosis drugs. We constructed photo-cross-linker probes containing a minimalist diazirine and an alkynyl handle of four TB drugs─pretomanid, linezolid, moxifloxacin, and one newly identified inhibitor, BB2-50F, with diverse chemical structures and mechanisms of action. We validated that these probes retain on-target activity against M. tuberculosis in growth and viability assays. Cross-linking and target identification using M. tuberculosis cell lysates produced results consistent with the known mechanism of each compound. The linezolid probe did not identify any proteins, consistent with linezolid binding to rRNA rather than to proteins. The pretomanid probe bound its prodrug activator Ddn, as well as Rv1558, a Ddn homologue that we show through mutagenesis and complementation studies, can bind to PMD but is unable to activate it. In addition to known targets, multiple apparent off-targets were also identified. Overall, this work highlights affinity-based proteome profiling as a useful technique to identify protein targets of tuberculosis drugs and gain insights into the drug mechanism of action.

Read PDF

Similar papers

Open access Oct 2026

Pathway-Based Analysis of Metabolic Enzymes as Drug Targets

The identification of PabB protein as an essential metabolic drug target, coupled with screening of FDA-approved drugs as inhibitors, provides a promising framework for anti tubercular drug discovery.

D. Bhat, Bhupender Singh · 0 citations
2025

In-Silico Identification of MurX as a Novel Drug Target in Mycobacterium tuberculosis and Molecular Docking Analysis of Bergenin

Findings support MurX as a viable therapeutic target and Bergenin as a promising candidate for further anti-TB drug development, and lays the foundation for subsequent experimental validation and the design of novel therapeutics targeting resistant strains of Mtb.

Mohd Asif Siddiqui, Ravindra Kumar Jain, Abhilash Sharma · 0 citations
Open access Sep 2026

Fragment-based drug discovery strategy reveals an unprecedented allosteric binding site in Mycobacterium tuberculosis DNA gyrase.

Tuberculosis remains a serious public health threat and the leading infectious cause of death worldwide. Tuberculosis treatment requires at least four antimicrobial drugs and is associated with adverse effects and prolonged therapy, compromising adherence and increasing the risk of drug resistance. Therefore, developin...

Sabrina T. Shiroma, Nicolas O. Rossini, Jillian F. Armenia et al. · 0 citations
Open access Oct 2026

Chemical Biology‐Based Drug Discovery Workflow Highlights Target Identification as a Key Step in Developing a Novel, Potent, and Selective GLUT1 Inhibitor

Discovery of bioactive compounds with novel chemical scaffolds remains a cornerstone of drug discovery. We designed a spiro scaffold composed of a cyclic imide and a diazepane to construct a focused compound library with minimal diversity. Screening for HCT‐116 cell growth inhibition, supported by growth curve analysis...

H. Kamiyama, Y. Onizawa, K. Kubara et al. · 0 citations
Open access

Experimental Evolution of Drug Resistance for Antibiotic Target Discovery in Chlamydia trachomatis.

The recent application of experimental and computational drug discovery workflows has identified hundreds of new molecules that display potent, and in some cases highly selective, activity against bacteria of the genus Chlamydia. The full value of these novel antichlamydial molecules, however, depends critically on our...

Aakriti Singh, B. S. Sixt · 0 citations
Open access Sep 2026

Integrated In Silico Analysis Reveals ABC Transporter ATP-Binding Protein as a Therapeutic Target in Helicobacter pylori

Helicobacter pylori remains a major cause of gastric diseases, while increasing antimicrobial resistance highlights the need for novel therapeutic targets. Here, we developed a comprehensive computational target-prioritization framework integrating Rosetta Stone domain-fusion analysis, subtractive genomics, metabolic p...

Manish Kumar, Hulikal Shivashankar Santosh kumar, B. Kumar et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.